Regeneron Pharmaceuticals, Inc.
REGN
$769.51
$2.850.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.99% | -1.40% | 1.43% | -2.68% | 12.04% |
| Total Other Revenue | 33.00% | 73.56% | 75.98% | -29.94% | -15.58% |
| Total Revenue | 2.51% | 0.90% | 3.62% | -3.70% | 10.33% |
| Cost of Revenue | 11.79% | 13.28% | 16.17% | 6.51% | 16.72% |
| Gross Profit | -7.62% | -10.23% | -7.67% | -15.44% | 4.11% |
| SG&A Expenses | -2.17% | -7.92% | -16.42% | -8.13% | 7.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.80% | 6.76% | 6.03% | 2.26% | 13.91% |
| Operating Income | -11.86% | -10.76% | -1.68% | -21.94% | 1.66% |
| Income Before Tax | 8.93% | 18.10% | -6.72% | 29.16% | -16.51% |
| Income Tax Expenses | 392.82% | 99.02% | -35.09% | 552.11% | 436.67% |
| Earnings from Continuing Operations | -7.97% | 8.91% | -2.84% | 12.01% | -20.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.97% | 8.91% | -2.84% | 12.01% | -20.86% |
| EBIT | -11.86% | -10.76% | -1.68% | -21.94% | 1.66% |
| EBITDA | -8.93% | -8.70% | -0.34% | -17.68% | 2.69% |
| EPS Basic | -3.76% | 13.64% | -0.07% | 13.16% | -21.60% |
| Normalized Basic EPS | 77.68% | -6.94% | 3.24% | -14.54% | 6.27% |
| EPS Diluted | -2.64% | 18.02% | 3.22% | 15.95% | -20.81% |
| Normalized Diluted EPS | 79.88% | -3.32% | 6.66% | -12.45% | 7.27% |
| Average Basic Shares Outstanding | -4.37% | -4.16% | -2.78% | -1.02% | 0.94% |
| Average Diluted Shares Outstanding | -5.54% | -7.75% | -5.89% | -3.39% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |